"Yay! They were approved for FebriDx. Too bad theymissed the opportunity to be first to market. Now there are better, faster, platforms already locked into that space."
Can you elaborate on what instrument-free solution is out there in US market? AFAIK, there are none and this is the differentiator for POC diagnostics. Mass market need with no price barrier.
As for ViraDx, who can say but maybe there was only marginal effort to build on our existing CoviDx IP? It was never going to be the make or break for the company. It does however, add one more product to be bundled together with FebriDx. If we want product sales to outstrip commercial services topline (LT strategy), we need to be able to provide a suite of POC kits to physicians. Some will be differentiated, some substitutable.
The R&D spend and approval chances of only developing untapped use cases that are first to market isn't realistic, unless you're happy to constantly tip in for CRs.
I'm sure there are at least a handful who've come on board after the FebriDx FDA approval; very different outlook. Good luck and hope this investment works out for you.
AIMHO. DYOR.
Add to My Watchlist
What is My Watchlist?
